Drug Pricing & Patents
Drug Pricing & Patents
HIV Medical Providers Call for Fair Drug Pricing to Expand Access to Treatment
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 December 2012 00:00
- Written by Liz Highleyman
Practitioners from the American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA) delivered a joint statement to pharmaceutical company executives this week, asking the industry to reconsider its pricing for antiretroviral drugs so that more people in the U.S. and worldwide are able to access treatment. 
DHHS Implements Common Application for HIV Patient Assistance Programs
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Press Release
A common application that allows people with HIV to apply for financial assistance for drugs from multiple companies went into effect on September 12, 2012. Individuals should now be able to obtain a complete antiretroviral regimen with a single form.
Companies Lower HIV Drug Prices for ADAP, but Many Patients Still Waiting
- Details
- Category: ADAP
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
Four pharmaceutical companies recently agreed to discount their prices on 
antiretroviral drugs for AIDS Drug Assistance Programs (ADAPs), which are under increasing pressure due to the ongoing financial crisis. More than 4000 people with HIV are currently on ADAP waiting lists, most of them in the Southeast U.S.
AIDS 2012: HIV Drugs Cheaper than Thought, Clinton Report Says
- Details
- Category: HIV Treatment
- Published on Friday, 03 August 2012 00:00
- Written by Press Release
Antiretroviral therapy and related care for people with HIV worldwide would likely cost about 4 times less than previously estimated, meaning that wider global scale-up of treatment is possible, according to a new report by the Clinton Health Access Initiative released ahead of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. 
Medicines Patent Pool Licenses First HIV and HBV Drugs
- Details
- Category: Drug Pricing & Patents
- Published on Monday, 18 July 2011 00:00
- Written by Press Release
UNITAID and the Medicines Patent Pool -- an initiative to make drugs more widely available at reduced cost -- announced its first pharmaceutical company agreement. Gilead Sciences licensed 4 drugs, including the popular tenofovir for treatment of HIV and hepatitis B, as well as coformulation including Truvada and the experimental Quad pill.
Web Design and Development by